Enliven Therapeutics (ELVN) Shares Outstanding (2019 - 2026)

Enliven Therapeutics has disclosed Shares Outstanding across 8 years of filings, most recently posting $60.9 million for Q1 2026.

• Shares Outstanding for Q1 2026 came in at $60.9 million, up 24.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $60.9 million (up 24.17% YoY), and the FY2025 annual result was $59.4 million, up 21.46% from the prior year.
• Shares Outstanding came in at $60.9 million for Q1 2026 at Enliven Therapeutics, up from $59.4 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $61.7 million in Q2 2022 to a low of $3.6 million in Q1 2022.
• The 5-year median for Shares Outstanding is $48.9 million (2024), against an average of $48.9 million.
• Across the five-year window, Shares Outstanding sank 80.13% in 2022 and soared 1056.4% in 2023, its largest moves.
• Enliven Therapeutics' Shares Outstanding stood at $61.7 million in 2022, then tumbled by 33.11% to $41.3 million in 2023, then increased by 18.51% to $48.9 million in 2024, then rose by 21.46% to $59.4 million in 2025, then gained by 2.44% to $60.9 million in 2026.
• The last three Shares Outstanding figures came in at $60.9 million (Q1 2026), $59.4 million (Q4 2025), and $59.3 million (Q3 2025), per Business Quant data.